Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.50M$1.50Mderived+106.3% vs Q4 2019 Net Income-$36.61M-$36.61MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$37,513,000N/M Operating Cash Flowderived-$29,216,000N/M Free Cash Flowderived-$30,383,000N/M Margins · derivedOperating margin-2497.5%+1672.1 pt vs Q4 2019
Net margin-2437.6%+1595.9 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 25, 2021 · 56 d after period end